Silo Pharma Inc.’s (SILO) Ketamine Study Produces Positive Endpoint Results, Suggests Topical Formulation Reduces Neuropathic Nerve Pain

• Silo recently completed ketamine study showing neuropathic nerve pain reduction when administered with patented, partnered delivery system
• Results of study demonstrated Silo’s topical ketamine formulation reduced mechanical allodynia and hyperalgesia at both the pre-and post-dosing time points, mechanical hyperalgesia reduced on day seven at the pre-dose time point
• Ketamine typically used to induce and maintain anesthesia, drug use expanding to include depression and chronic pain treatment at subanesthetic doses

Silo Pharma (OTCQB: SILO), a developmental stage biopharmaceutical company, recently completed a study of its ketamine formulation, showing nerve pain reduction when administered using a patented delivery system developed in partnership with Zylo Therapeutics (https://ibn.fm/BBCWC).

Results of the small animal study produced positive endpoint results, demonstrating that Silo’s topical ketamine formulation reduced mechanical allodynia and hyperalgesia at both the pre-and post-dosing time points. Mechanical hyperalgesia was additionally reduced on day seven at the pre-dose time point.

“These positive results of our study show that Silo is able to successfully formulate and deliver ketamine topically at reduced dosage to achieve its endpoint of pain reduction,” said Eric Weisblum, CEO of Silo Pharma. “This data is extremely promising for patients suffering from fibromyalgia and rheumatoid arthritis. Additionally, I am delighted to report that day seven and day nine scores averaged zero (no erythema or swelling present) for all groups, which bodes extremely well for our planned toxicology study.”

Ketamine is typically used to induce and maintain anesthesia. The medication can produce a trance-like state that provides sedation, amnesia, and pain relief (https://ibn.fm/NT1z3). While some anesthetic agents often employed cause serious side effects (https://ibn.fm/Mot9g), ketamine anesthesia typically preserves airway reflexes and breathing while stimulating heart function and increasing blood pressure. 

Interest in ketamine has expanded beyond traditional uses to include treatment for depression (https://ibn.fm/8gWGf) and chronic pain (https://ibn.fm/iBhlg) at subanesthetic doses. The drug is on the World Health Organization’s List of Essential Medicines (https://ibn.fm/So2Wx) and has been referred to as a “major advance in the treatment of depression of the past 50 years” (https://ibn.fm/SpOCU).

Silo Pharma aims to leverage the effects of ketamine via a patented administration method developed in partnership with Zylo Therapeutics Inc. called “Z-pod”. The company’s ketamine study aimed to demonstrate that Z-pod can hold and distribute ketamine and time-release the drug while diminishing potential hallucinogenic side effects. Besides ketamine, Z-pod is also being tested by Silo for other medicines, including psilocybin.

Silo Pharma Inc. is dedicated to researching and developing innovative pharmaceutical solutions that help people suffering from indications such as chronic pain, rheumatoid arthritis, fibromyalgia, post-traumatic stress disorder (“PTSD”), Parkinson’s disease, Alzheimer’s disease, and other rare neurological disorders. The company identifies and partners with leading medical universities, providing financial resources that catalyze the progress of cutting-edge research through the clinical stage and into commercialization. 

For more information, visit the company’s website at www.SiloPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.